A Comparison of Pentosan Polysulphate and Heparin II: Effects of Subcutaneous Injection

Summary

A comparison has been made between the effects of pentosan polysulphate (SP54) and mucosal heparin following subcutaneous injection in man. Unlike heparin, pentosan polysulphate has relatively little effect in vivo as measured by anti-factor Xa clotting assay and none by an anti-Xa amidolytic assay (S-2222). However, pentosan polysulphate is at least as potent as heparin on a weight basis in producing activation of lipoprotein lipase, shortening of the euglobulin clot lysis time and impairing the generation of factor Xa. Our data indicate that pentosan polysulphate has more marked effects in vivo than in vitro, that the action of the drug on clotting is mediated mainly via an At III-independent pathway, and that its effects are not confined to the coagulation system.

Key words

Pentosan polysulphate - Heparin - SP54 - Mechanism in vivo - Subcutaneous injection

• References

• 1 Joffe S. Drug prevention of postoperative deep vein thrombosis. A comparative study of calcium heparinate and sodium pentosan polysulfate. Arch Surg 1976; 111: 37-40
• 2 Bergqvist D, Efsing HO, Hallböök T, Lindblad B. Prevention of postoperative thromboembolic complications. A prospective comparison between Dextran 70, Dihydroergotamin-Heparin and a sulphated polysaccharid. Acta Chir Scand 1980; 146: 559-568
• 3 Bergqvist D, Ljungner H. A comparative study of Dextran 70 and a sulphated polysaccharide in the prevention of postoperative thromboembolic complications. Br J Surg 1981; 68: 449-451
• 4 Soria C, Soria J, Ryckewaert JJ, Holmer E, Caen JP. Anticoagulant activities of a pentosane polysulphate: comparison with standard heparin and a fraction of low molecular weight heparin. Thromb Res 1980; 19: 455-463
• 5 Czapek EE, Kwaan HC, Szczecinski M. The effect of a sulfated polysaccharide on antithrombin III. J Lab Clin Med 1980; 95: 783-790
• 6 Vinazzer H, Haas S, Stemberger A. Influence on the clotting mechanism of sodium pentosan polysulphate (SP54) in comparison to commercial beef lung sodium heparin. Thromb Res 1980; 20: 57-68
• 7 Halse Th. Aktivierung der Fibrinolyse und Thrombolyse durch Polysaccharidschwefelsäureester (Heparin, Heparinoide). Arzneim Forschung 1962; 12: 574-582
• 8 Thomas DP, Lane DA, Michalski R, Johnson EA, Kakkar VV. A heparin analogue with specific action on antithrombin III. Lancet 1977; 1: 120-122
• 9 Kakkar VV, Lawrence D, Bentley PG, De Haas HA, Ward VP, Scully MF. A comparative study of low doses of heparin and a heparin analogue in the prevention of postoperative deep vein thrombosis. Thromb Res 1978; 13: 111-122
• 10 Thomas DP, Barrowcliffe TW, Merton RE, Stocks J, Dawes J, Pepper DS. In vivo release of anti-Xa clotting activity by a heparin analogue. Thromb Res 1980; 17: 831-840
• 11 Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583
• 12 Thomas DP, Merton RE, Lewis WE, Barrowcliffe TW. Studies in man and experimental animals of a low molecular weight heparin fraction. Thromb Haemostas 1981; 45: 214-218
• 13 Fischer AM, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate and heparin. I. Mechanism of action. Thromb Haemostas 1982; 47: 104
• 14 Nilsson-Ehle P, Schotz NC. A stable radioactive substrate emulsion for assay of lipoprotein lipase. J Lipid Res 1976; 17: 536
• 15 Nilsson IM, Olow B. Fibrinolysis induced by streptokinase in man. Acta Chir Scand 1962; 123: 247-266
• 16 Marsh NA. Measurement of fibrinolytic capacity by the euglobulin lysis time method – a problem of “units”. Thromb Res 1977; 12: 197-200
• 17 Eika C, Godal HC, Kierulf P. Detection of small amounts of heparin by the thrombin clotting time. Lancet 1972; 2: 376
• 18 Marsh NA, Gaffney PJ. Some observations on the release of extrinsic and intrinsic plasminogen activators during exercise in man. Haemostasis 1980; 9: 238-247
• 19 Barrowcliffe TW, Johnson EA, Eggleton CA, Kemball-Cook G, Thomas DP. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haematol 1979; 41: 573-583
• 20 Rosenberg RD, Oosta GM, Jordan RE, Gardner WT. Mechanism of antithrombin action and the structural basis of heparin’s anticoagulant function. In: Chemistry and Biology of Heparin. Eds. Lundblad RL, Brown WV, Mann KG, Roberts HR. 249-269 Elsevier; North Holland: 1981
• 21 Ofosu F, Blajchmann MA, Hirsh J. The inhibition by heparin of the intrinsic pathway activation of Factor X in the absence of antithrombin III. Thromb Res 1980; 20: 391-403
• 22 Walker FJ, Esmon CT. Interactions between heparin and factor Xa. Inhibition of prothrombin activation. Biochim Biophys Acta 1979; 585: 405-415
• 23 Markwardt F, Klöcking HP. Heparin-induced release of plasminogen activator. Haemostasis 1977; 6: 370-374
• 24 Bergqvist D, Nilsson IM. A sulphated polysaccharide – the effects in vivo and in vitro on the haemostatic system in healthy volunteers. Thromb Res 1981; 23: 309-315